Advertisement
Advertisement

LUMO

LUMO logo

Lumos Pharma Inc

4.35
USD
+0.01
+0.23%
Dec 11, 15:59 UTC -5
Closed
...

Lumos Pharma Inc Profile

About

Lumos Pharma Inc. is a clinical stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's product pipeline consists of LUM-201 which is in clinical stage. Lumos Pharma Inc., formerly known as NewLink Genetics Corporation, is based in AUSTIN, Texas.

Info & Links

CEO

Richard J. Hawkins

Headquarters

4200 MARATHON BLVD.,SUITE 200
AUSTIN, TX 78756, UNITED STATES

Auditor

KPMG LLP

Share holders

66

Employees

33

Lumos Pharma Inc Statistics

Valuation Measures

Market Capitalization2

37.63M

Enterprise Value

24.11M

Enterprise Value/EBITDA(ttm)

-0.66

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

17.02

Price to Book(mrq)

7.18

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1583.49%

Profit Margin(ttm)

-2512.16%

Return on Equity(ttm)

-233.03%

Return on Invested Capital(ttm)

-319.95%

Return on Assets(ttm)

-129.88%

Income Statement

Revenue(ttm)

2.21M

Revenue Per Share(ttm)

0.25

Gross Profit(ttm)

2.21M

EBITDA(ttm)3

-36.31M

Net Income Available to Common(ttm)

-34.92M

Diluted EPS(ttm)

-4.29

Share Statistics

Beta (5Y Monthly)

0.74

52-Week Change

40.32%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

8.65M

Dividend Yield

0.00%

Float4

6.45M

% Held by Insiders

25.40%

% Held by Institutions

33.99%

Balance Sheet

Total Cash(mrq)

13.52M

Total Cash Per Share(mrq)

1.56

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.66%

Quick Ratio(mrq)

2.66%

Book Value Per Share(mrq)

0.57

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.92

Free Cash Flow(ytd)

-24.28M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement